The cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023

Thursday, February 28, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Feb. 27, 2019 /PRNewswire/ -- About this marketCholangiocarcinoma is one of the rare types of cancers globally,

as a result, the market does not have approved therapies in abundance. The dominance of these drugs is affecting the interest of new vendors to conduct research on developing novel therapies. To overcome this challenge, several research institutes are
coming up with various programs to treat patients with intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. The support from the institute is also coming in the form of new chemotherapy combinations for treating both types of cholangiocarcinoma. Similarly, various other research institutions are also working on providing treatment to the patients, and the increasing support from these institutes is expected to contribute significantly to the growth of the global cholangiocarcinoma therapeutics market during the forecast period. Technavio's analysts have predicted that the cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023.Download the full report: https://www.reportbuyer.com/product/5745773 Market OverviewGrowing usage of combination thereThe global cholangiocarcinoma therapeutics market has a limited number of treatment options, among which the most preferred treatment option is surgeries due to the lack of efficacy of therapeutics in the late stages of the disease. To overcome this, the market is witnessing an increase in the use of combination of chemotherapies to treat the disease.Dominance of surgeryThe global cholangiocarcinoma therapeutics market faces a heavy threat from surgeries, as they are currently the most preferred treatment option available to the patients. As a result, surgeries are gaining popularity for the treatment of both intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, which is expected to have a negative impact on the growth of the global cholangiocarcinoma therapeutics market during the forecast period.For the detailed list of factors that will drive and challenge the growth of the cholangiocarcinoma therapeutics market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fairly concentrated and with the presence of few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Download the full report: https://www.reportbuyer.com/product/5745773 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-cholangiocarcinoma-therapeutics-market-will-register-a-cagr-of-almost-6-by-2023-300803141.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store